TABLE 2.
Tumor status of breast cancer participants.
| Combined N = 123 (100%) | BMX recipients N = 61 (49.6%) | Non‐BMX recipients N = 62 (50.4%) | |
|---|---|---|---|
| Cancer stage | |||
| DCIS/LCIS | 22 (17.9%) | 11 (18.0%) | 11 (17.7%) |
| Stage 1 | 45 (36.6%) | 25 (41.0%) | 20 (32.3%) |
| Stage 2 | 41 (33.3%) | 15 (24.6%) | 26 (41.9%) |
| Stage 3 | 15 (12.2%) | 10 (16.4%) | 5 (8.1%) |
| Tumor grade | |||
| G1 | 43 (35.0%) | 20 (32.8%) | 23 (37.1%) |
| G2 | 36 (29.3%) | 21 (34.4%) | 15 (24.2%) |
| G3 | 22 (17.9%) | 9 (14.8%) | 13 (21.0%) |
| Missing | 22 (17.9%) | 11 (18.0%) | 11 (17.7%) |
| Estrogen receptor status | |||
| Positive | 98 (79.7%) | 50 (82.0%) | 48 (77.4%) |
| Negative | 16 (13.0%) | 7 (11.5%) | 9 (14.5%) |
| Unknown | 9 (7.3%) | 4 (6.6%) | 5 (8.1%) |
| Progesterone receptor status | |||
| Positive | 86 (70.0%) | 42 (68.8%) | 44 (71.0%) |
| Negative | 26 (21.1%) | 14 (23.0%) | 12 (19.4%) |
| Unknown | 11 (8.9%) | 5 (8.2%) | 6 (9.7%) |
| HER2/neu status | |||
| Positive | 24 (19.5%) | 13 (21.3%) | 11 (17.7%) |
| Negative | 77 (62.6%) | 40 (65.6%) | 37 (59.7%) |
| Unknown | 22 (17.9%) | 8 (13.1%) | 14 (22.6%) |
| Germline BRCA1/2 testing results | |||
| Positive a | 8 (6.5%) | 7 (11.5%) | 1 (1.6%) |
| Negative | 94 (76.4%) | 47 (77.0%) | 47 (75.8%) |
| Not tested | 20 (16.3%) | 7 (11.5%) | 13 (21.0%) |
| Missing | 1 (0.8%) | 0 (0.0%) | 1 (1.6%) |
| Germline BRCA1/2 testing in relation to treatment decision | |||
| Before | 71 (57.7%) | 36 (59.0%) | 35 (56.4%) |
| After | 33 (26.8%) | 18 (29.5%) | 15 (24.2%) |
| Not tested | 19 (15.5%) | 7 (11.5%) | 12 (19.4%) |
| Missing | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
a
Positive for a pathogenic variant.